Oramed Pharmaceuticals Stock
€2.15
Your prediction
Oramed Pharmaceuticals Stock
Oramed is a pharmaceutical company that focuses on the development of innovative oral delivery solutions for drugs that are traditionally administered through injection. The company is primarily dedicated to the development of an oral insulin capsule that can potentially revolutionize the treatment of diabetes. Their flagship product, ORMD-0801, is currently in Phase III clinical trials in the United States and has received Fast Track designation from the FDA. Oramed is a publicly traded company listed on the Nasdaq under the ticker symbol ORMP.
Pros and Cons of Oramed Pharmaceuticals in the next few years
Pros
Cons
Performance of Oramed Pharmaceuticals vs. its peers
Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
---|---|---|---|---|---|---|---|
Oramed Pharmaceuticals | -0.320% | 1.301% | 0.786% | -10.765% | 3.025% | -87.929% | -21.583% |
Enlivex Therapeutics Ltd. | -0.710% | 6.818% | 25.893% | -4.082% | -37.054% | -82.805% | -93.816% |
Ardelyx Inc. | 0.360% | 8.325% | 21.084% | 62.744% | 6.713% | 445.841% | 45.472% |
Evolus Inc | 0.660% | 4.861% | 7.857% | 83.030% | 66.851% | 135.938% | - |